

New assessment report from JNHB

Tibsovo for treatment of cholangiocarcinoma

JNHB have finalized and published their first joint assessment report after the re-launch in June 2024. The assessment report will be used in the national decision processes and is available on [Joint Nordic HTA-Bodies](#). The timepoint for decision will depend on national processes for oral cancer treatments.

In this assessment of Tibsovo for treatment of cholangiocarcinoma, NOMA was assessor, TLV co-assessor and DMC and Landspitali reviewers. Tibsovo is an out-patient drug in Finland, which means that the product is not within Fimeas remit. Therefore, Fimea was observers during the assessment.

Fact about this assessment:

Assessment time was 92 working days.